imiquimod has been researched along with Melanoma in 138 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (0.72) | 18.2507 |
2000's | 47 (34.06) | 29.6817 |
2010's | 65 (47.10) | 24.3611 |
2020's | 25 (18.12) | 2.80 |
Authors | Studies |
---|---|
Bonnet, PA; Bressolle, F; David, N; Deleuze-Masquefa, C; Gayraud-Paniagua, S; Khier, S; Moarbess, G; Pinguet, F | 1 |
Carvajal, R; Khan, S; Levin, M; Satish, T; Yoon, AJ | 1 |
Bevilacqua, F; Bleeker, MCG; Bornstein, J; Carcopino, X; Chargari, C; Cruickshank, ME; Erzeneoglu, BE; Esat Temiz, B; Gallio, N; Gultekin, M; Heller, D; Joura, E; Kesic, V; Planchamp, F; Preti, M; Querleu, D; Reich, O; Stockdale, CK; Van Beurden, M; Vieira-Baptista, P; Woelber, L; Zodzika, J | 1 |
Bevilacqua, F; Bleeker, MCG; Bornstein, J; Carcopino, X; Chargari, C; Cruickshank, ME; Erzeneoglu, BE; Gallio, N; Gultekin, M; Heller, D; Joura, E; Kesic, V; Planchamp, F; Preti, M; Querleu, D; Reich, O; Stockdale, CK; Temiz, BE; Van Beurden, M; Vieira-Baptista, P; Woelber, L; Zodzika, J | 1 |
Daniel, C; Kaushik, M; Neumann, I; Patalay, R; Timlin, H | 1 |
Bai, Y; Fang, X; Fu, B; Huang, H; Li, X; Ma, C; Meng, Z; Miao, W; Qian, C; Ren, H; Tao, X; Wang, A; Yang, Z | 1 |
Cen, L; Chen, X; Chu, Y; Dai, H; Feng, X; Huang, S; Ke, Y; Liu, B; Liu, Q; Qian, X; Zhang, Z | 1 |
Caimi, AT; Morilla, MJ; Perez, AP; Ramirez, C; Romero, EL | 1 |
Katyal, P; Lynch, KT; Meneveau, MO; Olson, WC; Slingluff, CL; Tran, CA | 1 |
Carr, M; Correa, L; Culbreth, A; Cunningham, K; DePalo, DK; Harkins, A; Longbottom, B; Patel, N; Puleo, C; Reed, R; Seminario-Vidal, L; Ward, C; Zager, JS | 1 |
Boyle, GM; Cullen, JK; Parsons, PG; Simmons, JL | 1 |
Barton, VR; Cheng, MY; Kao, J; Kirane, AR; Kiuru, M; Ma, C; Maverakis, E; Petukhova, TA; Wang, EA | 1 |
Choi, JN; Shetty, A; Sosman, J; Sunshine, JC | 1 |
Asinari, J; Feliciani, C; Goldust, M; Lotti, T; Pedrazzi, G; Satolli, F; Zucchi, A | 1 |
Dika, E; Lambertini, M; Melotti, B; Patrizi, A; Ravaioli, GM; Scarfì, F; Veronesi, G | 1 |
Frank, LA; Gazzi, RP; Guterres, SS; Onzi, G; Pohlmann, AR | 1 |
Abadir, W; Alavi, N; Look Hong, NJ; Nadler, A; Wright, FC | 1 |
Dika, E; Lambertini, M; Melotti, B; Mussi, M; Patrizi, A; Scarfì, F; Tartari, F; Veronesi, G | 1 |
Hignett, E; Khachemoune, A; Nguyen, K | 1 |
Chambers, M; Chapman, MS; O'Hern, K; Ryan, C | 1 |
Benedetto, C; Bertero, L; Bevilacqua, F; Borella, F; Carosso, AR; Cassoni, P; Castellano, I; Collemi, G; Cosma, S; Gallio, N; Micheletti, L; Preti, M | 1 |
Gesing, M; Hlebowicz, M; Iżycka-Świeszewska, E; Nowicki, RJ; Sikorska, M; Smiatacz, T; Sobjanek, M; Sokołowska-Wojdyło, M; Sławińska, M | 1 |
Basehore, BM; Globerson, JA; Nessel, T; Saleeby, ER | 1 |
Chianese-Bullock, KA; Deacon, D; Grosh, WW; Lynch, KT; Meneveau, MO; Olson, WC; Patterson, JW; Petroni, GR; Salerno, EP; Slingluff, CL; Smolkin, M; Woodson, E | 1 |
Chapman, MS; Park, AJ; Paul, J; Samie, FH | 1 |
Lv, R; Sun, Q | 1 |
Aranda Lopez, P; Freichel, M; Hartmann, AK; Radsak, MP; Schild, H; Stassen, M; Zajac, M | 1 |
Schwarz, T; Wehkamp, U | 1 |
Read, T; Schaider, H; Smithers, BM; Soyer, HP; Thomas, J; Wagels, M; Webber, S | 1 |
Cheng, MY; Kirane, A; Kulkarni, R; Luxardi, G; Ma, C; Maverakis, E; Monjazeb, AM; Ogawa, H | 1 |
Casanova, JM; García-de-la-Fuente, MR; Gatius, S; Huerva, V; Martí, RM; Matas-Nadal, C; Ortega, E; Sòria, X; Vilardell, F | 1 |
Arnaiz, B; Bocanegra Gondan, AI; Cobaleda-Siles, BM; Escors, D; García-Granda, MJ; Gato, M; Gómez Blanco, N; Llop, J; Mareque-Rivas, JC; Padro, D; Ruiz-de-Angulo, A; Zabaleta, A | 1 |
Delman, KA; Farley, CR; Lopez-Aguiar, AG; Lowe, MC; Oh, G; Russell, MC | 1 |
Alfano, R; Argenziano, G; Corneli, P; DI Brizzi, EV; Donadio, C; Moscarella, E; Zalaudek, I | 1 |
Calonje, E; Craythorne, E; Lewis, F; Nath, R; Veraitch, O | 1 |
Caruntu, C; Constantin, MM; Draghici, CC; Lisievici, CV; Lupu, M; Popa, AV; Sebe, TI; Solomon, I; Vajaitu, C; Voiculescu, VM | 1 |
Hsia, HC; Kim, S; Narayan, D; Norwich-Cavanaugh, A; Tsay, C | 1 |
Bassukas, IM; Gaitanis, G | 1 |
Halpern, AC; Quigley, EA | 1 |
Bajek, A; Czajkowski, R; Drewa, T; Schwartz, RA; Uzarska, M; Zegarska, B | 1 |
Banzhaf, CA; Jemec, GB; Mogensen, M; Ring, HC; Themstrup, L | 1 |
Cohen, DN; Johnson, DB; Joseph, RW; Kelley, MC; Likhari, SS; Powers, JG; Shinn, L; Sosman, JA; Wallender, EK; Zwerner, JP | 1 |
Bourgault-Villada, I; Clerici, T; Elfatoiki, FZ; Longvert, C; Roudier-Pujol, C; Saiag, P; Vasseur, E | 1 |
Chen, YJ; Huang, SW; Kao, JK; Lee, HC; Liang, SM; Shieh, JJ; Wang, ST; Wu, CY | 1 |
Fields, J; Fields, K; Jewell, T; Milikowski, C | 1 |
Aspord, C; Charles, J; Leccia, MT; Leloup, C; Molens, JP; Plumas, J; Tramcourt, L | 1 |
Ambrosini, M; Bruijns, SC; de Gruijl, TD; Fehres, CM; Hooijberg, E; Kalay, H; Unger, WW; van Beelen, AJ; van Kooyk, Y | 1 |
Hanlon, A; Lazova, R; Narayan, D; Sue, GR | 1 |
Costa, C; Mascolo, M; Palmisano, F; Russo, D; Scalvenzi, M | 1 |
D'Errico, A; De Giorgi, V; Gori, A; Grazzini, M; Massi, D; Papi, F; Savarese, I; Vannucchi, M | 1 |
Annessi, G; Didona, B; Didona, D; Napolitano, M | 1 |
Khaiboullina, SF; Lombardi, VC; Rizvanov, AA | 1 |
Apalla, Z; Chan, AW; Kyrgidis, A; Mocellin, S; Pilati, P; Tzellos, T | 1 |
Ariyan, S; Choi, JN; Geiger, EJ; Narayan, D; Pandit, AS | 1 |
Oranges, CM; Sisti, A; Sisti, G | 1 |
Chen, YJ; Chen, YY; Huang, SW; Kao, JK; Liang, SM; Shieh, JJ; Wang, ST; Wu, CY | 1 |
Chen, FW; Egbert, BM; Kim, DD; Swetter, SM | 1 |
Galan, A; Higgins, HW; Lee, KC; Leffell, DJ | 1 |
Barrio, MM; Mordoh, J; Pizzurro, GA; Podhajcer, OL; Sganga, L; Tapia, IJ | 1 |
Burrall, BA; Christensen, SD; Fitzmaurice, SD; Fung, MA; Garcia, MS; Joo, J; King, B; Konia, T; Leventhal, J; Martinez, S; Maverakis, E; Monjazeb, AM; Patel, F; Shi, VY; Tran, K; Wilken, R | 1 |
Abd Elmageed, ZY; Brodell, RT; El-Khattouti, A; Haikel, Y; Hannig, M; Hassan, M; Hassan, SY; Kandil, E; Leverkus, M; Megahed, M; Selimovic, D; Taylor, EB | 1 |
Baradad, M; Martí, R; Nagore, E; Ortiz-Brugués, A; Requena, C; Rivas-Tolosa, N; Sanmartín, V; Soriano, V; Toledo-Pastrana, T; Traves, V | 1 |
Chang, SE; Lee, MW; Lee, YJ; Rhee, do Y; Won, CH; Won, KH | 1 |
Bagaria, S; Cappel, M; Gilstrap, C; Jambusaria-Pahlajani, A; Joseph, RW; Swaika, A; Tzou, K | 1 |
Chianese-Bullock, KA; Clark, RA; Deacon, DH; Galeassi, N; Marincola, FM; Mauldin, IS; Mullins, DW; Olson, WC; Petroni, GR; Slingluff, CL; Smith, KT; Smolkin, ME; Stowman, AM; Teague, JE; Wages, NA; Wang, E | 1 |
Grady, BE; Spencer, JM | 1 |
Gioia Di Chiacchio, N; Haneke, E; le Voci, F; Ocampo-Garza, J; Paschoal, FM | 1 |
Brodland, DG; Murphy, ME; Zitelli, JA | 1 |
Adams, S; Angiulli, A; Angiulli, F; Berman, RS; Berner, N; Bhardwaj, N; Chiriboga, L; Cruz, CM; Gnjatic, S; Hardin, E; Hoffman, EW; Holman, RM; Jungbluth, A; Manches, O; Nonaka, D; O'Neill, DW; Old, L; Pan, L; Pavlick, AC; Ritter, E; Shao, Y; Shapiro, RL; Siu, K; Venhaus, RR | 1 |
Belonwu, N; Bodman-Smith, MD; Dalgleish, AG; Fischer, MD; Green, DS | 1 |
Harth, W; Heber, G; Helbig, D; Pönitzsch, I; Simon, JC; Wetzig, T | 1 |
Eickenscheidt, L; Kowalzick, L | 1 |
Fosko, SW; Missall, TA | 1 |
Uhara, H | 1 |
Dengel, LT; Grosh, WW; Harris, RC; Patterson, JW; Slingluff, CL; Turza, K; White, K | 1 |
Bonnet, PA; Bressolle, FM; Cooper, JF; Deleuze-Masquéfa, C; Gattacceca, F; Khier, S; Margout, D; Moarbess, G; Pinguet, F; Solassol, I | 1 |
Bos, JD; Filippov, DV; Konijnenberg, D; Luiten, RM; Meeuwenoord, NJ; Melief, CJ; Picavet, DI; Tjin, EP; van den Boorn, JG; van der Veen, JP | 1 |
Erickson, C; Miller, SJ | 1 |
Ma, F; Zhang, C; Zhang, J | 1 |
Crawford, RI; Sadownik, LA | 1 |
Fosko, SW; Hurley, MY; Missall, TA | 1 |
Parlette, EC; Toren, KL | 1 |
Aires, D; Dusing, R; Meggison, A; Miller, AK | 1 |
Chen, SL; Fung, MA; Garcia, MS; Goodarzi, H; Martinez, SR; Maverakis, E; Miyamura, Y; Ono, Y; Phan, T; Wehrli, LN | 1 |
Botella-Estrada, R; Nagore, E | 1 |
Borden, E; Triozzi, PL; Tuthill, RJ | 1 |
Caminal, JM; Fabra, A; Ferreres, JR; Marcoval, J; Penín, RM; Piulats, JM | 1 |
Desmedt, E; Florin, V; Mortier, L; Vercambre-Darras, S | 1 |
Coyner, K; Loeffler, D | 1 |
Bentow, JJ; Bruhn, KW; Chang, PL; Comin-Anduix, B; Craft, N; Dauphine, C; Economou, JS; Greger, S; Haskell, J; Konishi, T; Lee, DK; Moy, L; Narayan, R; Nguyen, H; Ribas, A; Tsui, S; Vanchinathan, V; Vargas, HI | 1 |
Barbosa, VH; Beutner, KR; Bhushan, R; Bichakjian, CK; Chuang, TY; Duvic, M; Foote Hood, A; Grichnik, JM; Halpern, AC; Ho, VC; Johnson, TM; Smith Begolka, W; Sober, AJ; Swetter, SM; Tsao, H | 1 |
Bogatch, K; Carvajal, RD; Chapman, PB; Chi, DS; Costantino, PD; Flavin, M; Gardner, GJ; Pulitzer, MP; Schwartz, GK; Smyth, EC; Wolchok, JD | 1 |
Glaser, A; Kalb, ML; Koszik, F; Stary, G; Stingl, G | 1 |
Amberg, N; Colonna, M; Drobits, B; Grundtner, R; Hammer, M; Holcmann, M; Sibilia, M; Swiecki, M | 1 |
Cohen, JL; Ellis, LZ; High, W; Stewart, L | 1 |
Arbiser, JL; Bips, M; Bonner, MY; Kovach, C; Seidler, A | 1 |
Bachmann, MF; Baumgaertner, P; Dummer, R; Geldhof, C; Goldinger, SM; Hammann-Haenni, A; Kündig, TM; Michielin, O; Mihic-Probst, D; Prior, JO; Schwarz, K; Speiser, DE; Willers, J | 1 |
Moon, SD; Spencer, JM | 1 |
Pföhler, C; Reinhold, U; Tilgen, W; Ugurel, S; Wagner, A | 1 |
Bong, AB; Bonnekoh, B; Franke, I; Gollnick, H; Schön, M; Ulrich, J | 1 |
Binder, B; Cerroni, L; Kerl, H; Richtig, E; Smolle, J; Wolf, IH | 1 |
Awada, A; Heenen, M; Laporte, M; Mathieu, A; Petein, M; Velu, T; Vereecken, P | 1 |
Fisher, GH; Lang, PG | 1 |
Beyeler, M; Burg, G; Dummer, R; Morcinek, J | 1 |
Kerl, H; Kopera, D; Richtig, E; Wolf, IH | 1 |
Beiteke, U; Grabbe, S; Loquai, C; Luger, TA; Metze, D; Nashan, D; Rüping, KW | 1 |
Bignon, YJ; Chèvenet, C; Corbin-Duval, A; D'Incan, M; Déchelotte, P; Franck, F; Hesling, C; Madelmont, JC; Mansard, S; Souteyrand, P; Veyre, A | 1 |
Bong, AB; Drewniok, C; Eberle, J; Geilen, CC; Gollnick, H; Schön, M; Schön, MP; Wienrich, BG | 1 |
Leverkus, M | 1 |
Schön, M; Schön, MP | 1 |
Holcmann, M; Lührs, P; Meindl, S; Palamara, F; Sibilia, M; Stingl, G | 1 |
Huntley, A; Navi, D | 1 |
Astner, S; Curiel-Lewandrowski, C; Frankenthaler, RA; González, S; Swindells, KJ; Tahan, SR; Williams, CM | 1 |
Caron, D; Cebon, J; Chen, Q; Chen, W; Davis, ID; Dimopoulos, N; Hopkins, W; Jackson, H; Jefford, M; Maraskovsky, E; Masterman, KA; Parente, P; Shackleton, M; Tai, T | 1 |
Martín-García, RF; Muñoz, CM; Sánchez, JL | 1 |
Skinner, R | 1 |
Dummer, R; Urosevic, M | 1 |
Cheney, RT; Dawson, K; Zeitouni, NC | 1 |
Bieber, T; Haller, O; Tueting, T; Uerlich, M; Wenzel, J | 1 |
Grant-Kels, JM; Grin, CM; Kluk, M; Ray, CM | 1 |
Marincola, FM; Monsurró, V; Panelli, MC; Wang, E | 1 |
Botella-Estrada, R; Guillén, C; Nagore, E; Sanmartín, O | 1 |
Casado, M; González-Beato, M; Mayor, M; Miralles, L; Pizarro, A; Sigüenza, M; Vidaurrázaga, C | 1 |
Sondak, VK | 1 |
Cartwright, N; Coyle, A; Fitzgerald, KA; Mitchell, JA; Silverman, N | 1 |
Cruickshank, DJ; Lonsdale-Eccles, AA; Morgan, JM; Nagarajan, S | 1 |
Figl, R; Goerdt, S; Hildenbrand, R; Kettelhack, C; Schadendorf, D; Thoelke, A; Ugurel, S; Utikal, J; Zimpfer, A | 1 |
Chen, WR; Naylor, MF; Nordquist, RE; Perry, LA; Teague, TK | 1 |
Bug, R; Gille, J; Kaufmann, R; Kovács, A; Spieth, K; Wolter, M | 1 |
Bodman-Smith, MD; Dalgleish, AG; Fischer, MD; Green, DS | 1 |
Cerroni, L; Kerl, H; Kodama, K; Wolf, IH | 1 |
Choi, GS; Lee, JR; Park, JH; Shin, JH; Song, SU | 1 |
Fenske, NA; Glass, LF; Prakash, AV; Shistik, G | 1 |
Alkan, SS; Dumitru, CD; Gibson, SJ; Inglefield, JR; Larson, CJ; Lipson, KE; Tomai, MA; Vasilakos, JP | 1 |
Gore, ME; Horton, V; Moore, J; Owens, M; Savage, P; Witt, P | 1 |
Funk, JO; Schuler, G; Steinmann, A; von den Driesch, P | 1 |
Hengge, U | 1 |
26 review(s) available for imiquimod and Melanoma
Article | Year |
---|---|
Treatment of periocular lentigo maligna with topical 5% Imiquimod: a review.
Topics: Aminoquinolines; Eyelids; Humans; Hutchinson's Melanotic Freckle; Imiquimod; Melanoma; Skin Neoplasms | 2023 |
Topical treatments for skin cancer.
Topics: Administration, Cutaneous; Antineoplastic Agents; Carcinoma, Basal Cell; Clinical Trials as Topic; Diterpenes; Drug Delivery Systems; Fluorouracil; Humans; Hutchinson's Melanotic Freckle; Imiquimod; Keratosis, Actinic; Melanoma; Neoplasms, Squamous Cell; Photochemotherapy; Retinoids; Skin; Skin Neoplasms; Ultraviolet Rays | 2020 |
The role of topical imiquimod in melanoma cutaneous metastases: A critical review of the literature.
Topics: Administration, Topical; Aminoquinolines; Antineoplastic Agents; Humans; Imiquimod; Melanoma; Retrospective Studies; Skin Neoplasms | 2020 |
Current and emerging treatment options for metastatic melanoma: a focused review.
Topics: Antineoplastic Agents; B7-H1 Antigen; Cancer Vaccines; CTLA-4 Antigen; Humans; Imiquimod; Interferons; Ipilimumab; Melanoma; Programmed Cell Death 1 Receptor; Proto-Oncogene Proteins B-raf; Radiotherapy; Survival Rate | 2020 |
Is There a Place for Immune Checkpoint Inhibitors in Vulvar Neoplasms? A State of the Art Review.
Topics: Adjuvants, Immunologic; Alphapapillomavirus; Antineoplastic Agents; Carcinoma, Squamous Cell; Female; Humans; Imiquimod; Immune Checkpoint Inhibitors; Immunotherapy; Melanoma; Neuroendocrine Tumors; Paget Disease, Extramammary; Prognosis; Vulvar Neoplasms | 2020 |
A Network Meta-Analysis of Non-Melanoma Skin Cancer (NMSC) Treatments: Efficacy and Safety Assessment.
Topics: Aminoquinolines; Cryotherapy; Fluorouracil; Humans; Imiquimod; Melanoma; Photochemotherapy; PubMed; Skin Neoplasms | 2017 |
Mediators of Inflammation in Topical Therapy of Skin Cancers.
Topics: Administration, Topical; Aminoquinolines; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Cytokines; Diterpenes; Fluorouracil; Humans; Imiquimod; Inflammation; Melanoma; Neoplasm Metastasis; Skin; Skin Neoplasms; Toll-Like Receptor 7 | 2019 |
Microinvasive melanoma: cutaneous pharmacotherapeutic approaches.
Topics: Aged; Aged, 80 and over; Aminoquinolines; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Dicarboxylic Acids; Female; Fluorouracil; Geriatric Assessment; Humans; Imiquimod; Immunohistochemistry; Interferon-alpha; Male; Melanoma; Neoplasm Invasiveness; Pharmaceutical Preparations; Prognosis; Risk Assessment; Skin Neoplasms; Survival Analysis; Treatment Outcome | 2013 |
Chemoprevention of skin melanoma: facts and myths.
Topics: Aminoquinolines; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Cell Line, Tumor; Cell Transformation, Neoplastic; Chemoprevention; Curcumin; Flavonoids; Humans; Imiquimod; Melanoma; Melanoma, Cutaneous Malignant; Pigmentation; Randomized Controlled Trials as Topic; Resveratrol; Retinoids; Risk; Skin; Skin Neoplasms; Stilbenes; Tea; Treatment Outcome; Vitamin D | 2013 |
Localized diffuse melanosis associated with melanoma successfully treated with imiquimod cream 5%: a case report and review of the literature.
Topics: Administration, Cutaneous; Aged; Aminoquinolines; Antineoplastic Agents; Female; Humans; Imiquimod; Melanoma; Melanosis; Skin Neoplasms | 2014 |
Melanoma of the glans penis successfully treated with topical imiquimod: dermoscopy usefulness in clinical monitoring and review of the literature.
Topics: Administration, Cutaneous; Adult; Aminoquinolines; Antineoplastic Agents; Dermoscopy; Humans; Imiquimod; Male; Melanoma; Penile Neoplasms; Skin Neoplasms; Treatment Outcome | 2017 |
Plasmacytoid dendritic cells, a role in neoplastic prevention and progression.
Topics: Adjuvants, Immunologic; Aminoquinolines; Cancer Vaccines; Dendritic Cells; Disease Progression; Humans; Imiquimod; Immunotherapy; Melanoma; Neoplasms; Skin Neoplasms; T-Lymphocytes; Toll-Like Receptor 7; Toll-Like Receptors; Tumor Escape; Tumor Microenvironment | 2015 |
Interventions for melanoma in situ, including lentigo maligna.
Topics: Aminoquinolines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Humans; Hutchinson's Melanotic Freckle; Imiquimod; Male; Melanoma; Melanoma, Cutaneous Malignant; Nicotinic Acids; Randomized Controlled Trials as Topic; Skin Neoplasms | 2014 |
Topical treatment of melanoma skin metastases with imiquimod: a review.
Topics: Administration, Cutaneous; Aminoquinolines; Antineoplastic Agents; Drug Administration Schedule; Humans; Imiquimod; Melanoma; Skin Cream; Skin Neoplasms; Treatment Outcome | 2015 |
Melanoma in situ: Part II. Histopathology, treatment, and clinical management.
Topics: Administration, Topical; Aminoquinolines; Biopsy, Needle; Carcinoma in Situ; Female; Humans; Imiquimod; Immunohistochemistry; Immunotherapy; Injections, Intralesional; Interferon-alpha; Laser Therapy; Male; Melanoma; Melanoma, Cutaneous Malignant; Mohs Surgery; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Randomized Controlled Trials as Topic; Skin Neoplasms; Treatment Outcome | 2015 |
Treatment options in melanoma in situ: topical and radiation therapy, excision and Mohs surgery.
Topics: Aminoquinolines; Antineoplastic Agents; Humans; Hutchinson's Melanotic Freckle; Imiquimod; Melanoma; Mohs Surgery; Skin Neoplasms; Treatment Outcome | 2010 |
Managing melanoma in situ.
Topics: Aminoquinolines; Antineoplastic Agents; Humans; Imiquimod; Laser Therapy; Melanoma; Mohs Surgery; Skin Neoplasms | 2010 |
[Imiquimod in the treatment of lentigo maligna].
Topics: Adjuvants, Immunologic; Aged; Aged, 80 and over; Aminoquinolines; Antineoplastic Agents; Biopsy; Contraindications; Cryotherapy; Disease Progression; Drug Approval; Female; Humans; Hutchinson's Melanotic Freckle; Imiquimod; Male; Melanoma; Microscopy, Confocal; Mohs Surgery; Neoplasm Invasiveness; Skin Neoplasms; Treatment Outcome | 2011 |
[Cutaneous neoplasms].
Topics: Adjuvants, Immunologic; Aminoquinolines; Antimetabolites, Antineoplastic; Antineoplastic Agents; Biopsy; Bowen's Disease; Carcinoma, Basal Cell; Carcinoma, Merkel Cell; Carcinoma, Squamous Cell; Clinical Trials as Topic; Combined Modality Therapy; Cryotherapy; Diagnosis, Differential; Female; Fluorouracil; Hemangiosarcoma; HIV Infections; Humans; Imiquimod; Immunotherapy; Keratosis; Lymph Node Excision; Lymphatic Metastasis; Lymphoma; Male; Melanoma; Neoplasm Recurrence, Local; Photochemotherapy; Randomized Controlled Trials as Topic; Sarcoma, Kaposi; Skin; Skin Neoplasms; Time Factors | 2003 |
Imiquimod: unexpected killer.
Topics: Aminoquinolines; Antineoplastic Agents; Apoptosis; Humans; Imiquimod; Melanoma; Skin Neoplasms | 2004 |
Immune modulation and apoptosis induction: two sides of the antitumoral activity of imiquimod.
Topics: Adjuvants, Immunologic; Administration, Topical; Aminoquinolines; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Basal Cell; Caspases; Cytochrome c Group; Enzyme Activation; Humans; Imiquimod; Melanoma; Mitochondria; Models, Biological; Neoplasms; Ointments; Proto-Oncogene Proteins c-bcl-2; Skin Neoplasms; Vascular Neoplasms | 2004 |
Imiquimod 5 percent cream and the treatment of cutaneous malignancy.
Topics: Aminoquinolines; Antineoplastic Agents; Apoptosis; Bowen's Disease; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Cell Line, Tumor; Clinical Trials as Topic; Condylomata Acuminata; Drug Screening Assays, Antitumor; Female; Humans; Hutchinson's Melanotic Freckle; Imiquimod; Immunity, Cellular; Immunologic Factors; Keratoacanthoma; Keratosis; Male; Melanoma; Multicenter Studies as Topic; Mycosis Fungoides; Ointments; Paget Disease, Extramammary; Precancerous Conditions; Randomized Controlled Trials as Topic; Skin Neoplasms | 2004 |
Role of topical therapies in the management of cutaneous disease.
Topics: Adjuvants, Immunologic; Administration, Topical; Aminoquinolines; Condylomata Acuminata; Dermatitis, Atopic; Dermatitis, Seborrheic; Humans; Hutchinson's Melanotic Freckle; Imiquimod; Keratosis; Melanoma; Membrane Glycoproteins; Receptors, Cell Surface; Skin Diseases; Skin Diseases, Viral; Skin Neoplasms; Tacrolimus; Toll-Like Receptors | 2004 |
Role of imiquimod in skin cancer treatment.
Topics: Administration, Cutaneous; Aminoquinolines; Antineoplastic Agents; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Humans; Imiquimod; Immunologic Factors; Melanoma; Skin Neoplasms | 2004 |
A global approach to tumor immunology.
Topics: Adjuvants, Immunologic; Aminoquinolines; Cancer Vaccines; Combined Modality Therapy; Gene Expression Profiling; Genomics; Humans; Imiquimod; Immune System; Immunologic Surveillance; Immunotherapy; Inflammation; Interleukin-2; Melanoma; Neoplasms; T-Lymphocytes | 2004 |
[Topical treatment of melanoma skin metastases with imiquimod].
Topics: Administration, Topical; Aged; Aged, 80 and over; Aminoquinolines; Antineoplastic Agents; Head and Neck Neoplasms; Humans; Imiquimod; Male; Melanoma; Scalp; Skin Neoplasms | 2005 |
12 trial(s) available for imiquimod and Melanoma
Article | Year |
---|---|
Immunogenicity in humans of a transdermal multipeptide melanoma vaccine administered with or without a TLR7 agonist.
Topics: Adjuvants, Immunologic; Administration, Cutaneous; Adolescent; Adult; Aged; Cancer Vaccines; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Female; Freund's Adjuvant; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Imiquimod; Immunogenicity, Vaccine; Injections, Intradermal; Injections, Subcutaneous; Lipids; Male; Melanoma; Melanoma-Specific Antigens; Middle Aged; Skin Neoplasms; Time Factors; Toll-Like Receptor 7; Treatment Outcome; Vaccination; Vaccines, Subunit; Young Adult | 2021 |
Protocol for the TIDAL Melanoma Study: topical imiquimod or diphenylcyclopropenone for the management of cutaneous in-transit melanoma metastases-a phase II, single centre, randomised, pilot study.
Topics: Administration, Topical; Adolescent; Adult; Aged; Aged, 80 and over; Aminoquinolines; Antineoplastic Agents; Clinical Protocols; Cyclopropanes; Female; Humans; Imiquimod; Immunotherapy; Male; Melanoma; Middle Aged; Pilot Projects; Remission Induction; Research Design; Skin Neoplasms; Treatment Outcome; Young Adult | 2017 |
Optical coherence tomography imaging of non-melanoma skin cancer undergoing imiquimod therapy.
Topics: Aminoquinolines; Antineoplastic Agents; Carcinoma, Basal Cell; Female; Humans; Imiquimod; Keratosis, Actinic; Male; Melanoma; Prognosis; Reproducibility of Results; Sensitivity and Specificity; Skin Neoplasms; Tomography, Optical Coherence; Treatment Outcome | 2014 |
Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant.
Topics: Adjuvants, Immunologic; Adult; Aged; Aminoquinolines; Antibody Formation; Antigens, Neoplasm; Biopsy; Cancer Vaccines; Epitope Mapping; Erythema; Female; Humans; Imiquimod; Immunization; Male; Melanoma; Membrane Proteins; Middle Aged; Pilot Projects; Toll-Like Receptor 7 | 2008 |
Topical imiquimod and intralesional interleukin-2 increase activated lymphocytes and restore the Th1/Th2 balance in patients with metastatic melanoma.
Topics: Administration, Topical; Aged; Aged, 80 and over; Aminoquinolines; Biomarkers; Female; Flow Cytometry; Humans; Imiquimod; Immunotherapy, Active; Injections, Intralesional; Interferon Inducers; Interferon-gamma; Interleukin-2; Interleukin-4; Interleukin-5; Longitudinal Studies; Lymphocyte Activation; Male; Melanoma; Middle Aged; Skin Neoplasms; Statistics, Nonparametric; Th1 Cells; Th2 Cells | 2008 |
Topical treatment of cutaneous metastases of malignant melanoma using combined imiquimod and 5-fluorouracil.
Topics: Administration, Topical; Aged; Aged, 80 and over; Aminoquinolines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Imiquimod; Melanoma; Neoplasm Metastasis; Skin Neoplasms; Skin Ulcer; Treatment Outcome | 2012 |
Immunomodulation by imiquimod in patients with high-risk primary melanoma.
Topics: Administration, Topical; Adult; Aminoquinolines; Antineoplastic Agents; Combined Modality Therapy; Female; Humans; Imiquimod; Immunologic Factors; Male; Melanoma; Pilot Projects; Preoperative Care; Prospective Studies; Risk Factors; Skin; Skin Neoplasms; T-Lymphocytes; Toll-Like Receptor 7; Treatment Outcome | 2012 |
Nano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector CD8⁺ T-cell responses in melanoma patients.
Topics: Adjuvants, Immunologic; Aminoquinolines; Cancer Vaccines; CD8-Positive T-Lymphocytes; Flow Cytometry; Freund's Adjuvant; Humans; Imiquimod; Immunologic Memory; Ligands; Lipids; MART-1 Antigen; Melanoma; Nanoparticles; Oligodeoxyribonucleotides; Skin Neoplasms; Statistics, Nonparametric; Toll-Like Receptor 7; Toll-Like Receptor 9 | 2012 |
Death receptor-independent apoptosis in malignant melanoma induced by the small-molecule immune response modifier imiquimod.
Topics: Administration, Topical; Aminoquinolines; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Biopsy; Cell Line, Tumor; fas Receptor; Humans; Imidazoles; Imiquimod; Melanocytes; Melanoma; Membrane Glycoproteins; Proto-Oncogene Proteins c-bcl-2; Receptors, Tumor Necrosis Factor; Skin Neoplasms; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor-alpha | 2004 |
The impact of imiquimod, a Toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligand.
Topics: Adjuvants, Immunologic; Adult; Aged; Aminoquinolines; Antigens, Neoplasm; Antineoplastic Agents; Cancer Vaccines; CD8-Positive T-Lymphocytes; Cytokines; Dendritic Cells; Female; Humans; Imiquimod; Immunotherapy, Active; Male; MART-1 Antigen; Melanoma; Membrane Proteins; Middle Aged; Monophenol Monooxygenase; Neoplasm Proteins; Peptide Fragments | 2004 |
Phase I/II study of topical imiquimod and intralesional interleukin-2 in the treatment of accessible metastases in malignant melanoma.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Aminoquinolines; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Female; Humans; Imiquimod; Injections, Intralesional; Interleukin-2; Male; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Ointments; Skin Neoplasms; Treatment Outcome | 2007 |
A phase I clinical trial of imiquimod, an oral interferon inducer, administered daily.
Topics: Adult; Aged; Aminoquinolines; Carcinoma, Renal Cell; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Imiquimod; Interferon Inducers; Interferons; Kidney Neoplasms; Male; Melanoma; Middle Aged | 1996 |
100 other study(ies) available for imiquimod and Melanoma
Article | Year |
---|---|
New imidazo[1,2-a]quinoxaline derivatives: synthesis and in vitro activity against human melanoma.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; Imidazoles; Melanoma; Quinoxalines; Structure-Activity Relationship | 2009 |
Treatment of recurrent mucosal melanoma of the oral cavity with topical imiquimod and pembrolizumab achieves complete histopathologic remission.
Topics: Administration, Topical; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Imiquimod; Melanoma; Middle Aged; Mouth; Treatment Outcome | 2021 |
The European Society of Gynaecological Oncology (ESGO), the International Society for the Study of Vulvovaginal Disease (ISSVD), the European College for the Study of Vulval Disease (ECSVD) and the European Federation for Colposcopy (EFC) consensus statem
Topics: Carcinoma in Situ; Cidofovir; Colposcopy; Female; Genital Neoplasms, Female; Humans; Imiquimod; Melanoma; Melanoma, Cutaneous Malignant; Paget Disease, Extramammary; Pregnancy; Skin Neoplasms; Vulvar Neoplasms | 2022 |
The European Society of Gynaecological Oncology (ESGO), the International Society for the Study of Vulvovaginal Disease (ISSVD), the European College for the Study of Vulval Disease (ECSVD) and the European Federation for Colposcopy (EFC) Consensus Statem
Topics: Carcinoma in Situ; Colposcopy; Female; Humans; Imiquimod; Melanoma; Melanoma, Cutaneous Malignant; Paget Disease, Extramammary; Pregnancy; Skin Neoplasms; Squamous Intraepithelial Lesions; Vulvar Neoplasms | 2022 |
Tumor immunotherapy boosted by R837 nanocrystals through combining chemotherapy and mild hyperthermia.
Topics: Cell Line, Tumor; Chitosan; Humans; Hydrogels; Hyperthermia, Induced; Imiquimod; Immunotherapy; Melanoma; Nanoparticles | 2022 |
A dual-adjuvant neoantigen nanovaccine loaded with imiquimod and magnesium enhances anti-tumor immune responses of melanoma.
Topics: Adjuvants, Immunologic; Animals; Antigens; Cancer Vaccines; Humans; Imiquimod; Immunity; Immunotherapy; Magnesium; Melanoma; Mice | 2022 |
Topics: Apoptosis; Humans; Imiquimod; Lipids; Liposomes; Melanoma; Necrosis; Skin | 2022 |
Intratumoral IFN-γ or topical TLR7 agonist promotes infiltration of melanoma metastases by T lymphocytes expanded in the blood after cancer vaccine.
Topics: Adjuvants, Immunologic; Cancer Vaccines; Humans; Imiquimod; Interferon-gamma; Lymphocytes, Tumor-Infiltrating; Melanoma; T-Lymphocytes; Toll-Like Receptor 7 | 2023 |
Assessing the Efficacy of Imiquimod Use in Patients With Persistent Locally Advanced Melanoma In Situ
Topics: Aminoquinolines; Antineoplastic Agents; Humans; Imiquimod; Melanoma; Melanoma, Cutaneous Malignant; Retrospective Studies; Skin Neoplasms; Treatment Outcome | 2023 |
Non-surgical management of primary invasive melanoma.
Topics: Aged; Aminoquinolines; Antineoplastic Agents; Humans; Imiquimod; Melanoma; Skin Neoplasms; Treatment Outcome; Tretinoin | 2021 |
Successful Treatment of In-Transit Metastatic Melanoma in a Renal Transplant Patient With Combination T-VEC/Imiquimod Immunotherapy.
Topics: Biological Products; Biopsy; Combined Modality Therapy; Disease Management; Herpesvirus 1, Human; Humans; Imiquimod; Immune Checkpoint Inhibitors; Kidney Transplantation; Male; Melanoma; Middle Aged; Oncolytic Virotherapy; Treatment Outcome | 2020 |
Actinic keratosis: Treatment with imiquimod 3.75%-A comparative study between patients with previous in situ melanoma, patients with invasive melanoma and patients with negative history of melanoma.
Topics: Aminoquinolines; Humans; Imiquimod; Keratosis, Actinic; Melanoma; Skin Neoplasms | 2020 |
In transit melanoma and imiquimod: A case of disease progression.
Topics: Aminoquinolines; Antineoplastic Agents; Disease Progression; Humans; Imiquimod; Melanoma; Skin Neoplasms | 2020 |
New pectin-based hydrogel containing imiquimod-loaded polymeric nanocapsules for melanoma treatment.
Topics: Animals; Cell Line, Tumor; Humans; Hydrogels; Imiquimod; Melanoma; Nanocapsules; Pectins; Swine | 2020 |
Lesional therapies for in-transit melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclopropanes; Female; Follow-Up Studies; Humans; Imiquimod; Injections, Intralesional; Interleukin-2; Male; Melanoma; Middle Aged; Prognosis; Retrospective Studies; Skin Neoplasms; Survival Rate | 2020 |
In lieu of penectomy: complete resolution of penile melanoma in situ with topical imiquimod and tretinoin.
Topics: Administration, Topical; Aminoquinolines; Antineoplastic Agents; Humans; Imiquimod; Melanoma; Skin Neoplasms; Tretinoin | 2021 |
Dermoscopic Features of Giant Molluscum Contagiosum in a Patient with Acquired Immunodeficiency Syndrome.
Topics: Acquired Immunodeficiency Syndrome; Adult; Child, Preschool; Female; Humans; Imiquimod; Melanoma; Molluscum Contagiosum; Skin Neoplasms | 2020 |
Novel Treatment of In-Transit Metastatic Melanoma With Shave Excision, Electrodesiccation and Curettage, and Topical Imiquimod 5% Cream.
Topics: Aged, 80 and over; Chemotherapy, Adjuvant; Combined Modality Therapy; Curettage; Electrocoagulation; Humans; Imiquimod; Male; Melanoma; Skin Cream; Skin Neoplasms | 2021 |
Long-Term Outcomes of Melanoma In Situ Treated With Topical 5% Imiquimod Cream: A Retrospective Review.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Aminoquinolines; Antineoplastic Agents; Female; Follow-Up Studies; Humans; Imiquimod; Male; Melanoma; Neoplasm Recurrence, Local; Retrospective Studies; Skin Neoplasms; Treatment Outcome | 2017 |
9-Phenanthrol enhances the generation of an CD8
Topics: Adjuvants, Immunologic; Administration, Cutaneous; Aminoquinolines; Animals; Calcium; Cell Degranulation; Cell Movement; Dendritic Cells; Humans; Imiquimod; Immunity, Innate; Mast Cells; Melanoma; Mice; Mice, Inbred C57BL; Mice, Transgenic; Phenanthrenes; Protein Kinase Inhibitors; Skin; Skin Neoplasms; T-Lymphocytes, Cytotoxic; TRPM Cation Channels; Vaccination; Xenograft Model Antitumor Assays | 2017 |
Topical Imiquimod for Melanoma In Situ? A Word of Caveat.
Topics: Administration, Topical; Aminoquinolines; Antineoplastic Agents; Humans; Imiquimod; Melanoma; Skin Neoplasms | 2018 |
T Cells Dominate the Local Immune Response Induced by Intralesional IL-2 in Combination with Imiquimod and Retinoid for In-Transit Metastatic Melanoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Female; Follow-Up Studies; Humans; Imiquimod; Injections, Intralesional; Interleukin-2; Male; Melanoma; Middle Aged; Retinoids; Skin Neoplasms; T-Lymphocytes; Treatment Outcome | 2018 |
Immunocryosurgery as monotherapy for lentigo maligna or combined with surgical excision for lentigo maligna melanoma.
Topics: Adjuvants, Immunologic; Administration, Cutaneous; Aged; Aged, 80 and over; Aminoquinolines; Biopsy; Combined Modality Therapy; Cryosurgery; Dermatologic Surgical Procedures; Female; Humans; Hutchinson's Melanotic Freckle; Imiquimod; Immunotherapy; Melanoma; Skin; Skin Cream; Skin Neoplasms | 2018 |
Effective cancer immunotherapy in mice by polyIC-imiquimod complexes and engineered magnetic nanoparticles.
Topics: Animals; Antigen-Presenting Cells; Cancer Vaccines; Cell Death; Cell Line; Cell Line, Tumor; Cell Movement; Drug Synergism; Endocytosis; Endosomes; Imiquimod; Immunity, Innate; Immunization; Immunotherapy; Lymph Nodes; Magnetite Nanoparticles; Melanoma; Mice, Inbred C57BL; Nanotechnology; Neoplasms; Phospholipids; Poly I-C; Polyethylene Glycols | 2018 |
Recurrence Patterns after Primary Excision of Invasive Melanoma with Melanoma
Topics: Adult; Aged; Aged, 80 and over; Aminoquinolines; Antineoplastic Agents; Female; Humans; Imiquimod; Male; Margins of Excision; Melanoma; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Retrospective Studies; Skin Neoplasms | 2018 |
Serial excision and imiquimod for lentigo maligna melanoma: a proposal for a combined treatment.
Topics: Combined Modality Therapy; Humans; Hutchinson's Melanotic Freckle; Imiquimod; Melanoma; Skin Neoplasms | 2021 |
Management of vulval melanoma in situ with imiquimod.
Topics: Administration, Topical; Aged; Antineoplastic Agents; Biopsy; Female; Humans; Imiquimod; Melanoma; Microscopy, Confocal; Treatment Outcome; Vulva; Vulvar Neoplasms | 2019 |
An Algorithm for the Management of Residual Head and Neck Melanoma In Situ Using Topical Imiquimod: A Pilot Study.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Agents; Female; Head and Neck Neoplasms; Humans; Imiquimod; Male; Melanoma; Middle Aged; Neoplasm, Residual; Pilot Projects; Retrospective Studies; Skin Neoplasms | 2019 |
Long-term outcomes of imiquimod-treated lentigo maligna: add on cryosurgery to induce inflammation and increase efficacy?
Topics: Cryosurgery; Humans; Hutchinson's Melanotic Freckle; Imiquimod; Inflammation; Melanoma; Skin Neoplasms | 2020 |
Severe cutaneous and neurologic toxicity in melanoma patients during vemurafenib administration following anti-PD-1 therapy.
Topics: Adult; Aminoquinolines; Anaphylaxis; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Drug Eruptions; Female; Guillain-Barre Syndrome; Humans; Imiquimod; Indoles; Melanoma; Middle Aged; Nivolumab; Programmed Cell Death 1 Receptor; Skin Neoplasms; Sulfonamides; Vemurafenib | 2013 |
[In-transit metastasis in melanoma: Efficacy of topical imiquimod combined with carbon dioxide laser or with electrocautery].
Topics: Administration, Cutaneous; Adult; Aged; Aminoquinolines; Antineoplastic Agents; Combined Modality Therapy; Disease Progression; Electrocoagulation; Facial Neoplasms; Fatal Outcome; Humans; Imiquimod; Interferon-alpha; Laser Therapy; Lasers, Gas; Leg; Lymphatic Metastasis; Male; Melanoma; Palliative Care; Remission Induction; Sentinel Lymph Node Biopsy; Skin Neoplasms | 2014 |
Targeting aerobic glycolysis and HIF-1alpha expression enhance imiquimod-induced apoptosis in cancer cells.
Topics: Aminoquinolines; Animals; Antineoplastic Agents; Apoptosis; Benzoquinones; Cell Line, Tumor; Deoxyglucose; Drug Therapy, Combination; Gene Expression Regulation; Gene Silencing; Glycolysis; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Imiquimod; Keratinocytes; Lactams, Macrocyclic; Melanoma; Mice; Protein Biosynthesis; Protein Transport; Proto-Oncogene Proteins c-akt; Reactive Oxygen Species; Signal Transduction; STAT3 Transcription Factor; Toll-Like Receptor 7; Toll-Like Receptor 8; Transcription, Genetic; Up-Regulation | 2014 |
Imiquimod inhibits melanoma development by promoting pDC cytotoxic functions and impeding tumor vascularization.
Topics: Administration, Topical; Aminoquinolines; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Dendritic Cells; Disease Models, Animal; Down-Regulation; Fibroblast Growth Factors; Humans; Imiquimod; Interleukin-8; Melanoma; Mice; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Middle Aged; Neovascularization, Pathologic; Ribonuclease, Pancreatic; Skin Neoplasms; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2014 |
Topical rather than intradermal application of the TLR7 ligand imiquimod leads to human dermal dendritic cell maturation and CD8+ T-cell cross-priming.
Topics: Administration, Topical; Aminoquinolines; Cancer Vaccines; CD8-Positive T-Lymphocytes; Cross-Priming; Cytokines; Dendritic Cells; Humans; Imidazoles; Imiquimod; Injections, Intradermal; Ligands; MART-1 Antigen; Melanoma; Skin; Toll-Like Receptor 7 | 2014 |
Use of imiquimod for residual acral melanoma.
Topics: Administration, Cutaneous; Aged, 80 and over; Aminoquinolines; Antineoplastic Agents; Carcinoma in Situ; Female; Follow-Up Studies; Foot Diseases; Humans; Imiquimod; Male; Melanoma; Melanoma, Cutaneous Malignant; Skin Cream; Skin Neoplasms; Treatment Outcome | 2014 |
Acral lentiginous melanoma treated with topical imiquimod cream: possible cooperation between drug and tumour cells.
Topics: Administration, Topical; Aged, 80 and over; Aminoquinolines; Antineoplastic Agents; Female; Foot; Humans; Imiquimod; Melanoma; Skin Neoplasms; Treatment Outcome | 2015 |
Multifocal melanoma in situ of the penis treated with topical Imiquimod.
Topics: Adult; Aminoquinolines; Antineoplastic Agents; Biopsy; Humans; Imiquimod; Male; Melanoma; Penile Neoplasms; Penis | 2016 |
Using topical imiquimod for the management of positive in situ margins after melanoma resection.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Aminoquinolines; Antineoplastic Agents; Combined Modality Therapy; Drug Administration Schedule; Female; Humans; Imiquimod; Male; Melanoma; Middle Aged; Retrospective Studies; Skin Neoplasms; Treatment Outcome | 2015 |
Imiquimod-induced AMPK activation causes translation attenuation and apoptosis but not autophagy.
Topics: Adenosine Triphosphate; Aminoquinolines; AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Antineoplastic Agents; Apoptosis; Autophagy; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Cell Line, Tumor; Down-Regulation; Enzyme Activation; Gene Silencing; Humans; Imiquimod; Melanoma; Myeloid Cell Leukemia Sequence 1 Protein; Myeloid Differentiation Factor 88; Phosphorylation; Protein Biosynthesis; Protein Serine-Threonine Kinases; Signal Transduction; Skin Neoplasms; Toll-Like Receptor 7; Toll-Like Receptor 8 | 2015 |
Imiquimod 5% cream as primary or adjuvant therapy for melanoma in situ, lentigo maligna type.
Topics: Adjuvants, Immunologic; Administration, Topical; Aminoquinolines; Carcinoma in Situ; Chemotherapy, Adjuvant; Cohort Studies; Female; Follow-Up Studies; Humans; Hutchinson's Melanotic Freckle; Imiquimod; Male; Melanoma; Neoplasm Invasiveness; Neoplasm Staging; Retrospective Studies; Risk Assessment; Skin Cream; Skin Neoplasms; Survival Rate; Treatment Outcome | 2015 |
Cytokine-enhanced maturation and migration to the lymph nodes of a human dying melanoma cell-loaded dendritic cell vaccine.
Topics: Aminoquinolines; Animals; Cancer Vaccines; Cell Movement; Chemotaxis; Cytokines; Dendritic Cells; Humans; Imiquimod; Lymph Nodes; Matrix Metalloproteinase 9; Melanoma; Mice; Mice, Nude; Neoplasm Invasiveness; T-Lymphocytes | 2015 |
100% Complete response rate in patients with cutaneous metastatic melanoma treated with intralesional interleukin (IL)-2, imiquimod, and topical retinoid combination therapy: results of a case series.
Topics: Administration, Topical; Aminoquinolines; Cohort Studies; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Imiquimod; Injections, Intralesional; Interleukin-2; Male; Melanoma; Melanoma, Cutaneous Malignant; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Retinoids; Retrospective Studies; Risk Assessment; Skin Neoplasms; Treatment Outcome | 2015 |
Imiquimod-induced apoptosis of melanoma cells is mediated by ER stress-dependent Noxa induction and enhanced by NF-κB inhibition.
Topics: Aminoquinolines; Apoptosis; Calcium; Caspase 3; Caspase 9; Cell Line, Tumor; Cytochromes c; Endoplasmic Reticulum; Endoplasmic Reticulum Stress; Humans; Imiquimod; JNK Mitogen-Activated Protein Kinases; Melanoma; Membrane Potential, Mitochondrial; Mitochondria; NF-kappa B; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; Signal Transduction; X-Linked Inhibitor of Apoptosis Protein | 2016 |
Local cryosurgery and imiquimod: A successful combination for the treatment of locoregional cutaneous metastasis of melanoma: A case series.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Aminoquinolines; Antineoplastic Agents; Combined Modality Therapy; Cryosurgery; Female; Humans; Imiquimod; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Retrospective Studies; Skin Neoplasms | 2016 |
Successful treatment of multiple vemurafenib-induced keratoacanthomas by topical application of imiquimod cream: Confirmation of clinical clearance by dermoscopy.
Topics: Adjuvants, Immunologic; Administration, Cutaneous; Aged, 80 and over; Aminoquinolines; Antineoplastic Agents; Drug Eruptions; Female; Humans; Imiquimod; Indoles; Keratoacanthoma; Melanoma; Skin Neoplasms; Sulfonamides; Treatment Outcome; Vemurafenib | 2016 |
Treatment of in-transit and metastatic melanoma in two patients treated with ipilimumab and topical imiquimod.
Topics: Administration, Topical; Aged, 80 and over; Aminoquinolines; Antineoplastic Combined Chemotherapy Protocols; Humans; Imiquimod; Ipilimumab; Male; Melanoma; Middle Aged; Skin Neoplasms | 2016 |
Topical treatment of melanoma metastases with imiquimod, plus administration of a cancer vaccine, promotes immune signatures in the metastases.
Topics: Administration, Topical; Aged; Aminoquinolines; Antigens, Neoplasm; Antineoplastic Agents; Cancer Vaccines; Cell Movement; Cells, Cultured; Combined Modality Therapy; Cytokines; Enzyme-Linked Immunospot Assay; Female; Humans; Imiquimod; Lymphocytes, Tumor-Infiltrating; Male; Melanoma; Middle Aged; Neoplasm Staging; Peptide Fragments; Skin Neoplasms; T-Lymphocytes; Toll-Like Receptor 7; Transcriptome; Vaccines, Subunit | 2016 |
Topical imiquimod clears invasive melanoma.
Topics: Administration, Cutaneous; Aged; Aminoquinolines; Antineoplastic Agents; Head and Neck Neoplasms; Humans; Imiquimod; Male; Melanoma; Scalp; Skin Neoplasms | 2016 |
Subungual Melanoma In Situ Treated With Imiquimod 5% Cream After Conservative Surgery Recurrence.
Topics: Aged, 80 and over; Aminoquinolines; Antineoplastic Agents; Biopsy; Humans; Imiquimod; Male; Melanoma; Nails; Neoplasm Recurrence, Local; Skin Cream; Skin Neoplasms; Toes | 2017 |
Definitive surgical treatment of 24 skin cancers not cured by prior imiquimod therapy: a case series.
Topics: Aged; Aminoquinolines; Antineoplastic Agents; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Female; Humans; Imiquimod; Male; Melanoma; Middle Aged; Mohs Surgery; Skin Neoplasms; Treatment Outcome | 2008 |
Complete remission of cutaneous and subcutaneous melanoma metastases of the scalp with imiquimod therapy.
Topics: Aminoquinolines; Antineoplastic Agents; Head and Neck Neoplasms; Humans; Imiquimod; Male; Melanoma; Middle Aged; Remission Induction; Scalp; Skin Neoplasms; Treatment Outcome | 2009 |
Progress of multiple cutaneous and subcutaneous melanoma metastases of the face during imiquimod treatment.
Topics: Aged; Aminoquinolines; Antineoplastic Agents; Facial Neoplasms; Fatal Outcome; Humans; Imiquimod; Male; Melanoma; Skin Neoplasms; Treatment Failure | 2009 |
The use of imiquimod to minimize the surgical defect when excising invasive malignant melanoma surrounded by extensive melanoma in situ, lentiginous type.
Topics: Adjuvants, Immunologic; Aged, 80 and over; Aminoquinolines; Cheek; Female; Follow-Up Studies; Humans; Imiquimod; Male; Melanoma; Middle Aged; Neoplasm Invasiveness; Scalp; Skin Neoplasms; Wound Healing | 2009 |
[Diagnosis and treatment of non-melanoma skin neoplasm].
Topics: Aminoquinolines; Antineoplastic Agents; Biopsy; Imiquimod; Melanoma; Neoplasm Staging; Photochemotherapy; Prognosis; Skin Neoplasms | 2009 |
Effectiveness of imiquimod limited to dermal melanoma metastases, with simultaneous resistance of subcutaneous metastasis.
Topics: Administration, Cutaneous; Aminoquinolines; Antineoplastic Agents; Dermis; Female; Head and Neck Neoplasms; Humans; Imiquimod; Melanoma; Middle Aged; Skin Neoplasms; Subcutaneous Tissue; Treatment Outcome | 2010 |
Pharmacology of EAPB0203, a novel imidazo[1,2-a]quinoxaline derivative with anti-tumoral activity on melanoma.
Topics: Aminoquinolines; Animals; Antineoplastic Agents; Cell Line, Tumor; Dose-Response Relationship, Drug; Humans; Imidazoles; Imiquimod; Injections, Intraperitoneal; Injections, Intravenous; Male; Melanoma; Mice; Mice, Nude; Nitrosourea Compounds; Organophosphorus Compounds; Quinoxalines; Rats; Skin Neoplasms; Xenograft Model Antitumor Assays | 2010 |
Effective melanoma immunotherapy in mice by the skin-depigmenting agent monobenzone and the adjuvants imiquimod and CpG.
Topics: Adjuvants, Immunologic; Aminoquinolines; Animals; CD8-Positive T-Lymphocytes; Cell Proliferation; Dinucleoside Phosphates; Hydroquinones; Imiquimod; Immunoglobulin G; Immunotherapy; Injections, Subcutaneous; Killer Cells, Natural; Leukocyte Count; Lymphocyte Activation; Lymphocyte Depletion; Melanoma; Mice; Mice, Inbred C57BL; Pigmentation; Skin Neoplasms | 2010 |
The TLR7 agonists imiquimod and gardiquimod improve DC-based immunotherapy for melanoma in mice.
Topics: Aminoquinolines; Animals; Cell Proliferation; Cells, Cultured; Cytotoxicity, Immunologic; Dendritic Cells; Imidazoles; Imiquimod; Immunization; Lymphocyte Activation; Melanoma; Mice; Mice, Inbred C57BL; Spleen; Toll-Like Receptor 7 | 2010 |
Post-surgical treatment of melanoma in situ of the vulva with imiquimod.
Topics: Aged; Aminoquinolines; Antineoplastic Agents; Combined Modality Therapy; Female; Humans; Imiquimod; Melanoma; Vulvar Neoplasms | 2010 |
Lentiginous melanoma in situ treatment with topical imiquimod: need for individualized regimens.
Topics: Administration, Topical; Aged; Aged, 80 and over; Aminoquinolines; Female; Humans; Imiquimod; Male; Melanoma; Skin Neoplasms | 2010 |
Regression of internal melanoma metastases following application of topical imiquimod to overlying skin.
Topics: Administration, Topical; Aminoquinolines; Antineoplastic Agents; Disease Progression; Humans; Imiquimod; Male; Melanoma; Middle Aged; Neoplasm Staging; Skin Neoplasms | 2011 |
Complete regression of subcutaneous and cutaneous metastatic melanoma with high-dose intralesional interleukin 2 in combination with topical imiquimod and retinoid cream.
Topics: Administration, Topical; Aged, 80 and over; Aminoquinolines; Antineoplastic Combined Chemotherapy Protocols; Humans; Imiquimod; Injections, Intralesional; Interleukin-2; Male; Melanoma; Middle Aged; Retinoids; Skin Neoplasms | 2011 |
Re-inventing intratumoral immunotherapy for melanoma.
Topics: Aminoquinolines; Antineoplastic Agents; BCG Vaccine; Cytokines; Humans; Imiquimod; Immunotherapy; Injections, Intralesional; Melanoma; Neoplasm Recurrence, Local; Skin Neoplasms; Treatment Outcome | 2011 |
[Descriptive analysis of cutaneous recurrence patterns in patients with melanoma].
Topics: Aged; Aged, 80 and over; Aminoquinolines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dacarbazine; Female; Humans; Imiquimod; Kaplan-Meier Estimate; Lymph Node Excision; Male; Melanoma; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasms, Multiple Primary; Prognosis; Skin Neoplasms; Skin Ulcer | 2011 |
Topical imiquimod in the treatment of two cutaneous melanocytomas in a dog.
Topics: Administration, Topical; Aminoquinolines; Animals; Antineoplastic Agents; Dog Diseases; Dogs; Female; Imiquimod; Melanoma; Skin Neoplasms | 2012 |
Guidelines of care for the management of primary cutaneous melanoma. American Academy of Dermatology.
Topics: Aminoquinolines; Antineoplastic Agents; Asymptomatic Diseases; Cryotherapy; Diagnostic Imaging; Evidence-Based Medicine; Follow-Up Studies; Humans; Hutchinson's Melanotic Freckle; Imiquimod; Lymphatic Metastasis; Melanoma; Nail Diseases; Neoplasm Grading; Neoplasm Staging; Sentinel Lymph Node Biopsy; Skin Neoplasms | 2011 |
Treatment of locally recurrent mucosal melanoma with topical imiquimod.
Topics: Administration, Topical; Aged; Aminoquinolines; Antineoplastic Agents; Female; Humans; Imiquimod; Male; Melanoma; Middle Aged; Mouth Neoplasms; Neoplasm Recurrence, Local; Vaginal Neoplasms; Vulvar Neoplasms | 2011 |
TRAIL(+) human plasmacytoid dendritic cells kill tumor cells in vitro: mechanisms of imiquimod- and IFN-α-mediated antitumor reactivity.
Topics: Aminoquinolines; Cell Line, Tumor; Dendritic Cells; Humans; Imiquimod; Interferon Inducers; Interferon-alpha; Jurkat Cells; Melanoma; Neoplasms; TNF-Related Apoptosis-Inducing Ligand; Toll-Like Receptor 7; Toll-Like Receptor 8; Toll-Like Receptor 9 | 2012 |
Imiquimod clears tumors in mice independent of adaptive immunity by converting pDCs into tumor-killing effector cells.
Topics: Adaptive Immunity; Adjuvants, Immunologic; Aminoquinolines; Animals; Antineoplastic Agents; Cell Line, Tumor; Chemokine CCL2; Dendritic Cells; Humans; Imiquimod; Melanoma; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Mice, Knockout; Myeloid Differentiation Factor 88; Neoplasms, Experimental; Receptor, Interferon alpha-beta; Signal Transduction; Skin; Toll-Like Receptor 7 | 2012 |
Melanoma in situ treated successfully using imiquimod after nonclearance with surgery: review of the literature.
Topics: Administration, Topical; Aged, 80 and over; Aminoquinolines; Antineoplastic Agents; Biopsy; Facial Neoplasms; Follow-Up Studies; Humans; Imiquimod; Male; Melanoma; Mohs Surgery; Skin Neoplasms | 2012 |
Combination therapy of imiquimod and gentian violet for cutaneous melanoma metastases.
Topics: Aged, 80 and over; Aminoquinolines; Anti-Infective Agents, Local; Antineoplastic Agents; Chemoradiotherapy; Drug Therapy, Combination; Gentian Violet; Humans; Imiquimod; Male; Melanoma; Skin Neoplasms | 2012 |
Clearance of invasive melanoma with topical imiquimod.
Topics: Administration, Topical; Aged, 80 and over; Aminoquinolines; Antineoplastic Agents; Biopsy; Female; Frail Elderly; Humans; Imiquimod; Inflammation; Melanoma; Neoplasm Invasiveness; Skin; Skin Neoplasms | 2013 |
Topical imiquimod eradicates skin metastases of malignant melanoma but fails to prevent rapid lymphogenous metastatic spread.
Topics: Administration, Topical; Aged; Aged, 80 and over; Aminoquinolines; Antineoplastic Agents; Humans; Imiquimod; Lymphatic Metastasis; Male; Melanoma; Skin Neoplasms | 2002 |
Imiquimod, a topical immune response modifier, in the treatment of cutaneous metastases of malignant melanoma.
Topics: Adjuvants, Immunologic; Administration, Topical; Aged; Aged, 80 and over; Aminoquinolines; Antineoplastic Agents; Female; Humans; Imiquimod; Injections, Intralesional; Interleukin-2; Male; Melanoma; Skin Neoplasms | 2002 |
Topical imiquimod in the treatment of metastatic melanoma to skin.
Topics: Adjuvants, Immunologic; Administration, Cutaneous; Aged; Aged, 80 and over; Aminoquinolines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Dacarbazine; Female; Humans; Imiquimod; Interferon alpha-2; Interferon-alpha; Knee; Leg; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Nitrosourea Compounds; Organophosphorus Compounds; Recombinant Proteins; Scalp; Skin Neoplasms; Treatment Outcome | 2003 |
Management of cutaneous locoregional recurrences of melanoma: a new therapeutic perspective with imiquimod.
Topics: Administration, Topical; Aged; Aminoquinolines; Antineoplastic Agents; Female; Humans; Imiquimod; Melanoma; Neoplasm Recurrence, Local; Skin Neoplasms | 2003 |
Treatment of melanoma in situ on sun-damaged skin with topical 5% imiquimod cream complicated by the development of invasive disease.
Topics: Adjuvants, Immunologic; Administration, Topical; Aged; Aged, 80 and over; Aminoquinolines; Antineoplastic Agents; Facial Neoplasms; Female; Humans; Hutchinson's Melanotic Freckle; Imiquimod; Melanoma; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasms, Radiation-Induced; Skin Neoplasms | 2003 |
Locoregional cutaneous metastases of malignant melanoma and their management.
Topics: Aged; Aged, 80 and over; Aminoquinolines; Antineoplastic Agents; Female; Humans; Imiquimod; Lymphatic Metastasis; Male; Melanoma; Neoplasm Recurrence, Local; Neoplastic Cells, Circulating; Skin Neoplasms; Treatment Outcome | 2004 |
[Imiquimod, pegylated interferon-alpha-2b and interleukin-2 in the treatment of cutaneous melanoma metastases].
Topics: Adjuvants, Immunologic; Aged; Aminoquinolines; Antineoplastic Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Imiquimod; Injections, Intralesional; Interferon alpha-2; Interferon Inducers; Interferon-alpha; Interleukin-2; Melanoma; Neoplasm Metastasis; Recombinant Proteins; Skin Neoplasms; Time Factors | 2004 |
In vivo and in situ modulation of the expression of genes involved in metastasis and angiogenesis in a patient treated with topical imiquimod for melanoma skin metastases.
Topics: Administration, Topical; Aged; Aminoquinolines; Angiogenesis Inhibitors; Antineoplastic Agents; Female; Gene Expression Regulation; Humans; Imiquimod; Interferon-alpha; Kisspeptins; Matrix Metalloproteinases; Melanoma; Neovascularization, Pathologic; Proteins; Skin Neoplasms; Tissue Inhibitor of Metalloproteinase-1; Tumor Suppressor Proteins; Vascular Endothelial Growth Factors | 2004 |
Identification and characterization of pDC-like cells in normal mouse skin and melanomas treated with imiquimod.
Topics: Aminoquinolines; Animals; Antineoplastic Agents; Cell Movement; Dendritic Cells; Flow Cytometry; Imiquimod; Inflammation; Melanoma; Mice; Skin; Spleen | 2004 |
Use of in vivo confocal microscopy in malignant melanoma: an aid in diagnosis and assessment of surgical and nonsurgical therapeutic approaches.
Topics: Aminoquinolines; Biopsy, Needle; Facial Neoplasms; Follow-Up Studies; Humans; Imiquimod; Immunohistochemistry; Male; Melanoma; Microscopy, Confocal; Middle Aged; Mohs Surgery; Neoplasm Staging; Risk Assessment; Sampling Studies; Sensitivity and Specificity; Skin; Skin Neoplasms; Treatment Outcome | 2004 |
Successful treatment of persistent melanoma in situ with 5% imiquimod cream.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Aminoquinolines; Antineoplastic Agents; Drug Administration Schedule; Female; Humans; Imiquimod; Melanoma; Neck; Skin Neoplasms | 2004 |
Treatment of cutaneous metastatic melanoma with imiquimod 5% cream and the pulsed-dye laser.
Topics: Aged; Aged, 80 and over; Aminoquinolines; Antineoplastic Agents; Combined Modality Therapy; Humans; Imiquimod; Laser Therapy; Male; Melanoma; Skin Neoplasms | 2005 |
Minimizing surgery in skin cancer treatment. A new test looks for cancer in the lymph nodes during melanoma surgery, while a topical cream helps people with another form of skin cancer avoid the knife.
Topics: Adjuvants, Immunologic; Aminoquinolines; Antibodies, Neoplasm; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Basal Cell; Humans; Imiquimod; Lymphatic Metastasis; Melanoma; Skin Neoplasms | 2005 |
Enhanced type I interferon signaling and recruitment of chemokine receptor CXCR3-expressing lymphocytes into the skin following treatment with the TLR7-agonist imiquimod.
Topics: Adjuvants, Immunologic; Aminoquinolines; Breast Neoplasms; Carcinoma, Basal Cell; Chemotaxis, Leukocyte; Female; Humans; Imiquimod; Interferon Type I; Lymphocytes; Melanoma; Membrane Glycoproteins; Receptors, Cell Surface; Receptors, Chemokine; Receptors, CXCR3; Signal Transduction; Skin; Skin Neoplasms; Toll-Like Receptor 7; Toll-Like Receptors | 2005 |
Successful treatment of malignant melanoma in situ with topical 5% imiquimod cream.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Aminoquinolines; Antineoplastic Agents; Drug Administration Schedule; Facial Neoplasms; Female; Humans; Imiquimod; Male; Melanoma; Skin Neoplasms; Treatment Outcome | 2005 |
[Imiquimod for the treatment of skin metastases of melanoma].
Topics: Aged; Aged, 80 and over; Aminoquinolines; Antineoplastic Agents; Female; Humans; Imiquimod; Melanoma; Skin Neoplasms | 2005 |
Advances in the understanding and treatment of melanoma -- Keystone Symposium.
Topics: Aminoquinolines; Angiogenesis Inhibitors; Antineoplastic Agents; Biomarkers, Tumor; Humans; Imiquimod; Immunotherapy; Melanoma; Neoplasm Staging; Thalidomide; Toll-Like Receptors | 2006 |
TOLLing away in Brazil.
Topics: Adaptor Proteins, Signal Transducing; Aminoquinolines; Animals; Antineoplastic Agents; Antiprotozoal Agents; Brazil; Carcinoma, Basal Cell; Condylomata Acuminata; Diaminopimelic Acid; Drosophila melanogaster; Drosophila Proteins; Gene Expression Regulation; Gram-Negative Bacteria; Humans; Imiquimod; Immunity, Innate; Infections; Intracellular Signaling Peptides and Proteins; Lipopolysaccharides; Melanoma; Mice; Models, Immunological; Molecular Structure; Peptidoglycan; Protozoan Infections; Radiation Chimera; RNA Helicases; Signal Transduction; Skin Diseases; Skin Neoplasms; Substrate Specificity; Toll-Like Receptor 7; Toll-Like Receptors | 2006 |
Successful treatment of vulval melanoma in situ with topical 5% imiquimod cream.
Topics: Aged; Aminoquinolines; Antineoplastic Agents; Female; Humans; Imiquimod; Melanoma; Precancerous Conditions; Vulvar Neoplasms | 2006 |
Complete remission of multiple satellite and in-transit melanoma metastases after sequential treatment with isolated limb perfusion and topical imiquimod.
Topics: Aminoquinolines; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusion; Fatal Outcome; Female; Humans; Imiquimod; Melanoma; Middle Aged; Remission Induction; Skin Neoplasms | 2006 |
In situ photoimmunotherapy: a tumour-directed treatment for melanoma.
Topics: Aged; Aminoquinolines; Antineoplastic Agents; Combined Modality Therapy; Female; Humans; Imiquimod; Infrared Rays; Laser Therapy; Lung Neoplasms; Male; Melanoma; Middle Aged; Photochemotherapy; Photosensitizing Agents; Skin Neoplasms; Toll-Like Receptors; Treatment Outcome | 2006 |
Topical imiquimod: effectiveness in intraepithelial melanoma of oral mucosa.
Topics: Administration, Topical; Aged; Aminoquinolines; Antineoplastic Agents; Carcinoma in Situ; Female; Humans; Imiquimod; Melanoma; Mouth Mucosa; Mouth Neoplasms; Skin Neoplasms | 2006 |
Nature of inflammatory infiltrate in superficial cutaneous malignancies during topical imiquimod treatment.
Topics: Adjuvants, Immunologic; Aged; Aged, 80 and over; Aminoquinolines; Biomarkers, Tumor; Bowen's Disease; Carcinoma in Situ; Carcinoma, Basal Cell; Female; Humans; Hutchinson's Melanotic Freckle; Imiquimod; Inflammation; Keratosis; Male; Melanoma; Middle Aged; Skin Neoplasms | 2007 |
Combined treatment with intratumoral injection of dendritic cells and topical application of imiquimod for murine melanoma.
Topics: Administration, Topical; Aminoquinolines; Animals; Antineoplastic Agents; Combined Modality Therapy; Dendritic Cells; Female; Imiquimod; Immunotherapy, Adoptive; Injections, Intralesional; Melanoma; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Skin Neoplasms | 2007 |
Treatment of locally metastatic melanoma: a novel approach.
Topics: Administration, Cutaneous; Aged, 80 and over; Aminoquinolines; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Imiquimod; Melanoma; Neoplasm Metastasis; Neoplasm Recurrence, Local; Nicotinic Acids; Skin Neoplasms; Treatment Outcome | 2007 |
TLR7 agonist 852A inhibition of tumor cell proliferation is dependent on plasmacytoid dendritic cells and type I IFN.
Topics: Aminoquinolines; Animals; Cell Line, Tumor; Cell Proliferation; Cell Survival; Culture Media, Conditioned; Dendritic Cells; Humans; Imiquimod; Interferon Type I; Leukocytes, Mononuclear; Lung; Melanoma; Mice; Neoplasms; Oligodeoxyribonucleotides; Quinolines; Subcellular Fractions; Sulfonamides; Toll-Like Receptor 7; Toll-Like Receptor 9 | 2008 |
Topical imiquimod treatment of a cutaneous melanoma metastasis.
Topics: Adjuvants, Immunologic; Administration, Topical; Aminoquinolines; Female; Humans; Imiquimod; Melanoma; Middle Aged; Skin Neoplasms; Treatment Outcome | 2000 |
[Initial success with topical immunomodulators. A creme for skin cancer? (interview by Renate Jackle)].
Topics: Adjuvants, Immunologic; Aminoquinolines; Antineoplastic Agents; Carcinoma, Basal Cell; Humans; Imiquimod; Melanoma; Neoplasms, Radiation-Induced; Ointments; Radiodermatitis; Skin Neoplasms; Treatment Outcome | 2001 |